US Stock Insider Trading | Evommune disclosed 1 insider transaction on February 18

K-LinePoet · 2026-02-20T18:30:20+00:00

February 18, 2026, Evommune (EVMN) disclosed an internal transaction. Shareholder with over 10% stake, Verduyn-van Weegen Felice Isabel, purchased 358,700 shares on February 17, 2026.【Recent Internal Transactions】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share/USD | Total Amount/USD || --- | --- | --- | --- | --- | --- | --- | --- || February 18, 2026 | Shareholder with over 10% stake | Verduyn-van Weegen Felice Isabel | 2026

K-LinePoet

2026-02-20 18:30:20

On February 18, 2026, Evommune (EVMN) disclosed a single insider transaction. Shareholder holding more than 10%, Verduyn-van Weegen Felice Isabel, purchased 358,700 shares on February 17, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 18, 2026	Shareholder holding more than 10%	Verduyn-van Weegen Felice Isabel	February 17, 2026	Buy	358,700	27.88	10,000,000
February 17, 2026	Director	RA CAPITAL MANAGEMENT, L.P.	February 17, 2026	Buy	35,900	27.88	1,000,000
December 22, 2025	Shareholder holding more than 10%	Hopfner Robert Lorne	December 19, 2025	Buy	1,000	17.35	17,350
December 11, 2025	Executive	Drew Janice Suzann	December 9, 2025	Sell	5,074	17.84	85,300
December 11, 2025	Executive	Patel Jeegar Pravinkumar	December 9, 2025	Sell	7,513	17.84	134,000
December 11, 2025	Director	Bauer Eugene	December 9, 2025	Sell	1,478	17.84	23,600
December 11, 2025	Executive	Moss Gregory S.	December 9, 2025	Sell	13,600	17.84	243,100
November 12, 2025	Shareholder holding more than 10%	LSP 7 Cooperative UA	November 7, 2025	Buy	1,562,500	16.00	25,000,000
November 12, 2025	Shareholders holding more than 10%	RA CAPITAL MANAGEMENT, L.P., Verduyn-van Weegen Felice Isabel	November 7, 2025	Buy	2,812,500	16.00	45,000,000

[Company Information]

Evommune, Inc. is a company incorporated in Delaware in April 2020, headquartered in Palo Alto, California. It is a clinical-stage biotechnology company focused on developing innovative therapies targeting the primary pathogenic factors of chronic inflammatory diseases. Its initial clinical development projects focus on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.